Breaking News Instant updates and real-time market news.

NTB

Butterfield

$37.30 /

-0.18 (-0.48%)

06:07
04/25/19
04/25
06:07
04/25/19
06:07

Butterfield to acquire ABN AMRO Channel Islands for approximately $208M

The Bank of N.T. Butterfield & Son announced that it has entered into a definitive agreement to acquire ABN AMRO (Channel Islands) Limited, the Channel Islands-based banking business of ABN AMRO Bank N.V. through its wholly owned subsidiary, Butterfield Bank Limited, a company incorporated in Guernsey. The aggregate purchase price is approximately $208M, subject to certain purchase price adjustments. The transaction is anticipated to close during the third quarter, subject to regulatory and other customary closing conditions. After the Closing, ABN AMRO Channel Islands business and employees will be integrated with the existing Butterfield Guernsey operations and operate under the Butterfield name.

  • 25

    Apr

  • 30

    Apr

  • 01

    May

NTB Butterfield
$37.30 /

-0.18 (-0.48%)

01/15/19 Citi
Butterfield upgraded to Buy from Neutral at Citi
10/25/18 Wells Fargo
Butterfield price target lowered to $45 from $58 at Wells Fargo
10/24/18 Wells Fargo
Butterfield shares should be bought on post-earnings dip, says Wells Fargo
10/24/18 Keefe Bruyette
Butterfield selloff today 'seems severe,' says Keefe Bruyette

TODAY'S FREE FLY STORIES

General news
Asian Market Update: » 02:00
08/12/20
08/12
02:00
08/12/20
02:00

Asian Market Update:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Recommendations
Pliant Therapeutics' approach to fibrotic diseases best in industry, says Piper » 20:57
08/11/20
08/11
20:57
08/11/20
20:57
PLRX

Pliant Therapeutics

$26.44 /

-0.26 (-0.97%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren keeps his Overweight rating and $50 price target on Pliant Therapeutics after its Q2 results. The company's key IPF and PSC trials remains on track, while the newly announced program in severe COVID-19-related ARDS was also "intriguing", the analyst tells investors in a research note. Van Buren maintains a positive stance on Pliant's precision medicine approach to fibrotic diseases as a "best-in-industry approach to tackle the unmet need in fibrosis."

ShowHide Related Items >><<
PLRX Pliant Therapeutics
$26.44 /

-0.26 (-0.97%)

06/29/20 Needham
Pliant Therapeutics initiated with a Buy at Needham
06/29/20 Cowen
Pliant Therapeutics initiated with an Outperform at Cowen
06/29/20 Citi
Pliant Therapeutics initiated with a Buy at Citi
06/29/20 Piper Sandler
Pliant Therapeutics initiated with an Overweight at Piper Sandler
PLRX Pliant Therapeutics
$26.44 /

-0.26 (-0.97%)

  • 03
    Jun
PLRX Pliant Therapeutics
$26.44 /

-0.26 (-0.97%)

Earnings
Notable companies reporting before tomorrow's open » 20:25
08/11/20
08/11
20:25
08/11/20
20:25
EAT

Brinker

$30.14 /

+0.355 (+1.19%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include Brinker International (EAT), consensus ($1.43).

ShowHide Related Items >><<
EAT Brinker
$30.14 /

+0.355 (+1.19%)

EAT Brinker
$30.14 /

+0.355 (+1.19%)

08/07/20
Fly Intel: Top five analyst upgrades
08/07/20 Evercore ISI
Brinker upgraded to Outperform from In Line at Evercore ISI
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Jefferies
Brinker initiated with a Buy at Jefferies
EAT Brinker
$30.14 /

+0.355 (+1.19%)

  • 07
    May
EAT Brinker
$30.14 /

+0.355 (+1.19%)

EAT Brinker
$30.14 /

+0.355 (+1.19%)

Recommendations
Investors should own Gossamer Bio into important readouts, says Piper Sandler » 20:00
08/11/20
08/11
20:00
08/11/20
20:00
GOSS

Gossamer Bio

$13.30 /

-0.31 (-2.28%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren keeps his Overweight rating and $30 price target on Gossamer Bio after its Q2 results today. The analyst believes that investors should own the stock heading into "several important year-end data readouts", as success from any of its trials could lead to "significant upside" from the current levels.

ShowHide Related Items >><<
GOSS Gossamer Bio
$13.30 /

-0.31 (-2.28%)

GOSS Gossamer Bio
$13.30 /

-0.31 (-2.28%)

07/14/20 Cantor Fitzgerald
Gossamer Bio price target raised to $33 from $25 at Cantor Fitzgerald
06/29/20 H.C. Wainwright
Gossamer Bio initiated with a Buy at H.C. Wainwright
05/29/20 Piper Sandler
Piper says Gossamer's GB1275 well tolerated, early activity signs 'promising'
05/20/20 SVB Leerink
Gossamer Bio price target raised to $36 from $27 at SVB Leerink
GOSS Gossamer Bio
$13.30 /

-0.31 (-2.28%)

  • 19
    May
GOSS Gossamer Bio
$13.30 /

-0.31 (-2.28%)

Recommendations
Government awards for Moderna validates vaccine promise, says Piper Sandler » 19:50
08/11/20
08/11
19:50
08/11/20
19:50
MRNA

Moderna

$68.94 /

-3.09 (-4.29%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff keeps his Overweight rating and $134 price target on Moderna after the company announced a $1.525B order for 100M doses of mRNA-1273 from the U.S. government. The company has now earned a total of $2.48B from the U.S. as the government will have an option to purchase up to an additional 400M doses, the analyst tells investors in a research note, adding that the awards "validate the promise" of mRNA-1273. Tenthoff further states that Moderna is expected to provide an update in September regarding its Phase-3 COVE trial, which is now enrolling 30K Americans to receive mRNA-1273 or placebo.

ShowHide Related Items >><<
MRNA Moderna
$68.94 /

-3.09 (-4.29%)

MRNA Moderna
$68.94 /

-3.09 (-4.29%)

08/06/20 Barclays
Moderna COVID vaccine still has 'best-in-class potential,' says Barclays
08/05/20 Piper Sandler
Piper reiterates $134 target on Moderna, notes Q2 ended with $3.1B cash
08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
MRNA Moderna
$68.94 /

-3.09 (-4.29%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$68.94 /

-3.09 (-4.29%)

MRNA Moderna
$68.94 /

-3.09 (-4.29%)

MRNA Moderna
$68.94 /

-3.09 (-4.29%)

Recommendations
Alpine Immune Sciences price target lowered to $18 from $21 at Piper Sandler » 19:05
08/11/20
08/11
19:05
08/11/20
19:05
ALPN

Alpine Immune Sciences

$10.14 /

-0.39 (-3.70%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff lowered the firm's price target on Alpine Immune Sciences to $18 from $21 and keeps an Overweight rating on the shares after the company reported Q2 results. The analyst noted that Alpine will initiate a Phase II study of ALPN-101 next year, and is conducting the Phase I NEON-1 study of ALPN-202 in refractory.resistant solid tumor or lymphoma patients with data expected next year. Tenthoff said the price target cut is based on dilution from recent financing.

ShowHide Related Items >><<
ALPN Alpine Immune Sciences
$10.14 /

-0.39 (-3.70%)

ALPN Alpine Immune Sciences
$10.14 /

-0.39 (-3.70%)

06/19/20 Wedbush
Alpine Immune price target raised to $22 from $10 at Wedbush
06/18/20 Piper Sandler
Alpine Immune Sciences price target raised to $21 from $8 at Piper Sandler
06/04/20 Piper Sandler
Alpine data demonstrate application of platform technology, says Piper Sandler
04/27/20 Piper Sandler
Piper Sandler backs Overweight rating for Alpine after study design presented
ALPN Alpine Immune Sciences
$10.14 /

-0.39 (-3.70%)

ALPN Alpine Immune Sciences
$10.14 /

-0.39 (-3.70%)

Hot Stocks
Moody's acquires stake in Malaysian Rating Corporation Berhad » 19:01
08/11/20
08/11
19:01
08/11/20
19:01
MCO

Moody's

$274.62 /

+3.51 (+1.29%)

Moody's announced…

Moody's announced that it has acquired a minority stake in Malaysian Rating Corporation Berhad, or MARC, a credit rating agency serving the Malaysian domestic bond and sukuk markets. The investment "strengthens Moody's presence in Southeast Asia and across domestic bond markets globally, and advances its position as a leader in Islamic finance." MARC will continue to operate as an independent entity and will remain separate from Moody's Investors Service and its credit rating processes and activities. The investment was funded with cash on hand and is not expected to have a material effect on Moody's 2020 financial results.

ShowHide Related Items >><<
MCO Moody's
$274.62 /

+3.51 (+1.29%)

MCO Moody's
$274.62 /

+3.51 (+1.29%)

07/08/20 Goldman Sachs
Moody's price target raised to $295 from $258 at Goldman Sachs
06/08/20 BMO Capital
Moody's price target raised to $298 from $285 at BMO Capital
05/29/20 Credit Suisse
Moody's initiated with an Outperform at Credit Suisse
05/18/20 Oppenheimer
Moody's initiated with an Outperform at Oppenheimer
MCO Moody's
$274.62 /

+3.51 (+1.29%)

MCO Moody's
$274.62 /

+3.51 (+1.29%)

On The Fly
Fly Intel: After-Hours Movers » 18:54
08/11/20
08/11
18:54
08/11/20
18:54
CNR

Cornerstone Building Brands

$7.35 /

+0.1 (+1.38%)

, CMBM

Cambium Networks

$11.86 /

-0.31 (-2.55%)

, LRN

K12

$47.31 /

-0.73 (-1.52%)

, AOSL

Alpha & Omega

$11.44 /

+0.12 (+1.06%)

, KODK

Eastman Kodak

$10.01 /

-0.665 (-6.23%)

, CVET

Covetrus

$23.04 /

-0.64 (-2.70%)

, VIR

Vir Biotechnology

$52.70 /

-0.49 (-0.92%)

, TXG

10x Genomics

$96.78 /

+0.01 (+0.01%)

, MRNA

Moderna

$68.94 /

-3.09 (-4.29%)

, FBK

FB Financial

$28.63 /

+0.92 (+3.32%)

, TSLA

Tesla

$1,374.39 /

-45.48 (-3.20%)

, GIII

G-III Apparel

$11.99 /

+0.735 (+6.53%)

, OSPN

OneSpan

$31.19 /

+1.28 (+4.28%)

, IDN

Intellicheck

$8.32 /

+0.08 (+0.97%)

, RRGB

Red Robin

$10.85 /

+0.86 (+8.61%)

, YTEN

Yield10 Bioscience

$6.53 /

+0.38 (+6.18%)

, PLUG

Plug Power

$11.31 /

-0.73 (-6.06%)

, SMCI

Super Micro Computer

$30.45 /

+0.35 (+1.16%)

, HCAT

Health Catalyst

$34.96 /

-0.19 (-0.54%)

, LMND

Lemonade

$62.84 /

-4.44 (-6.60%)

, TRVN

Trevena

$2.72 /

-0.42 (-13.38%)

, PSNL

Personalis

$21.21 /

+0.17 (+0.81%)

, GFF

Griffon

$24.07 /

-0.285 (-1.17%)

, OSTK

Overstock.com

$91.92 /

-3.66 (-3.83%)

, ADVM

Adverum Biotechnologies

$15.59 /

-3.13 (-16.72%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
YTEN Yield10 Bioscience
$6.53 /

+0.38 (+6.18%)

VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

TXG 10x Genomics
$96.78 /

+0.01 (+0.01%)

TSLA Tesla
$1,374.39 /

-45.48 (-3.20%)

TRVN Trevena
$2.72 /

-0.42 (-13.38%)

SMCI Super Micro Computer
$30.45 /

+0.35 (+1.16%)

RRGB Red Robin
$10.85 /

+0.86 (+8.61%)

PSNL Personalis
$21.21 /

+0.17 (+0.81%)

PLUG Plug Power
$11.31 /

-0.73 (-6.06%)

OSTK Overstock.com
$91.92 /

-3.66 (-3.83%)

OSPN OneSpan
$31.19 /

+1.28 (+4.28%)

MRNA Moderna
$68.94 /

-3.09 (-4.29%)

LRN K12
$47.31 /

-0.73 (-1.52%)

LMND Lemonade
$62.84 /

-4.44 (-6.60%)

KODK Eastman Kodak
$10.01 /

-0.665 (-6.23%)

IDN Intellicheck
$8.32 /

+0.08 (+0.97%)

HCAT Health Catalyst
$34.96 /

-0.19 (-0.54%)

GIII G-III Apparel
$11.99 /

+0.735 (+6.53%)

GFF Griffon
$24.07 /

-0.285 (-1.17%)

FBK FB Financial
$28.63 /

+0.92 (+3.32%)

CVET Covetrus
$23.04 /

-0.64 (-2.70%)

CNR Cornerstone Building Brands
$7.35 /

+0.1 (+1.38%)

CMBM Cambium Networks
$11.86 /

-0.31 (-2.55%)

ADVM Adverum Biotechnologies
$15.59 /

-3.13 (-16.72%)

CNR Cornerstone Building Brands
$7.35 /

+0.1 (+1.38%)

06/15/20 Sidoti
Cornerstone Building Brands initiated with a Neutral at Sidoti
03/13/20 DA Davidson
Cornerstone Building Brands upgraded to Neutral at DA Davidson
03/13/20 DA Davidson
Cornerstone Building Brands upgraded to Neutral from Underperform at DA Davidson
11/19/19
Cornerstone Building Brands management to meet with Seaport Global
CMBM Cambium Networks
$11.86 /

-0.31 (-2.55%)

07/21/20 Roth Capital
Cambium Networks price target raised to $16 from $10.50 at Roth Capital
07/02/20 Roth Capital
USF ban for Huawei, ZTE should benefit Cambium, says Roth Capital
06/16/20 JPMorgan
Cambium Networks upgraded to Overweight from Neutral at JPMorgan
06/16/20 JPMorgan
Cambium Networks upgraded to Overweight from Neutral at JPMorgan
LRN K12
$47.31 /

-0.73 (-1.52%)

07/09/20 Sidoti
K12 downgraded to Neutral from Buy at Sidoti
06/04/20 BMO Capital
K12 price target raised to $32 from $30 at BMO Capital
01/28/20 Barrington
K12 price target lowered to $30 from $40 at Barrington
01/28/20 BMO Capital
K12 price target lowered to $23 from $27 at BMO Capital
AOSL Alpha & Omega
$11.44 /

+0.12 (+1.06%)

03/19/20 B. Riley FBR
B. Riley FBR downgrades 10 Semiconductor names on escalating risks
03/19/20 B. Riley FBR
Alpha & Omega downgraded to Neutral from Buy at B. Riley FBR
09/17/19 Loop Capital
Alpha & Omega growth trajectory encouraging, says Loop Capital
08/22/19 Loop Capital
Alpha & Omega price target raised to $18 from $13 at Loop Capital
KODK Eastman Kodak
$10.01 /

-0.665 (-6.23%)

CVET Covetrus
$23.04 /

-0.64 (-2.70%)

06/25/20 Guggenheim
PetIQ price target raised to $44 from $33.50 at Guggenheim
05/18/20 Spin-Off Research
Covetrus upgraded to Buy from Hold at Spin-Off Research
09/09/19 Goldman Sachs
Covetrus initiated with a Sell at Goldman Sachs
08/14/19 Stifel
Covetrus price target lowered to $18 from $30 at Stifel
VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

05/13/20 Barclays
Vir Biotechnology price target raised to $44 from $41 at Barclays
03/19/20 JPMorgan
JPMorgan downgrades Vir Biotechnology to Underweight after 290% rally
03/19/20 JPMorgan
Vir Biotechnology downgraded to Underweight from Neutral at JPMorgan
03/13/20 Goldman Sachs
Vir Biotechnology downgraded to Neutral from Buy at Goldman Sachs
TXG 10x Genomics
$96.78 /

+0.01 (+0.01%)

07/10/20
Fly Intel: Top five analyst initiations
07/09/20 Stifel
10x Genomics initiated with a Buy at Stifel
05/12/20 Cowen
10x Genomics price target raised to $85 from $68 at Cowen
03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
MRNA Moderna
$68.94 /

-3.09 (-4.29%)

08/06/20 Barclays
Moderna COVID vaccine still has 'best-in-class potential,' says Barclays
08/05/20 Piper Sandler
Piper reiterates $134 target on Moderna, notes Q2 ended with $3.1B cash
08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
FBK FB Financial
$28.63 /

+0.92 (+3.32%)

01/02/20 Truist
SunTrust raises price targets on select regional banks on improved margins
12/09/19 Sandler O'Neill
FB Financial downgraded to Hold from Buy at Sandler O'Neill
10/23/19 Raymond James
FB Financial downgraded to Market Perform on valuation at Raymond James
10/23/19 Raymond James
FB Financial downgraded to Market Perform from Outperform at Raymond James
TSLA Tesla
$1,374.39 /

-45.48 (-3.20%)

08/05/20 Piper Sandler
Piper calls Beyond Meat the Tesla of packaged food, ups price target
07/29/20 Morgan Stanley
Tesla price target raised to $1,050 from $740 at Morgan Stanley
07/28/20
Fly Intel: Top five analyst downgrades
07/28/20 Bernstein
Bernstein's Sacconaghi downgrades Tesla to sell on 'mind-boggling' valuation
GIII G-III Apparel
$11.99 /

+0.735 (+6.53%)

08/06/20
Fly Intel: Top five analyst downgrades
08/06/20 Barclays
Barclays downgrades G-III Apparel to Underweight on 'secular risk'
08/06/20 Barclays
G-III Apparel downgraded to Underweight from Equal Weight at Barclays
06/08/20
Fly Intel: Top five analyst downgrades
OSPN OneSpan
$31.19 /

+1.28 (+4.28%)

06/24/20 Needham
OneSpan price target raised to $31 from $24 at Needham
05/19/20
Fly Intel: Top five analyst initiations
05/19/20 Needham
OneSpan initiated with a Buy at Needham
05/18/20 Needham
OneSpan initiated with a Buy at Needham
IDN Intellicheck
$8.32 /

+0.08 (+0.97%)

03/12/20 B. Riley FBR
Intellicheck should be bought on recent pullback, says B. Riley FBR
01/08/20 B. Riley FBR
Intellicheck price target raised to $12 from $8 at B. Riley FBR
10/18/19
Fly Intel: Top five analyst initiations
10/18/19 B. Riley FBR
B. Riley FBR starts Intellicheck with Buy rating, $8 price target
RRGB Red Robin
$10.85 /

+0.86 (+8.61%)

06/11/20 Wells Fargo
Red Robin price target lowered to $14 from $30 at Wells Fargo
02/26/20 Wells Fargo
Red Robin price target lowered to $30 from $35 at Wells Fargo
01/15/20 Maxim
Red Robin seeing early signs of turnaround, says Maxim
11/06/19 Loop Capital
Red Robin price target lowered to $33 from $36 at Loop Capital
YTEN Yield10 Bioscience
$6.53 /

+0.38 (+6.18%)

12/11/19 Ladenburg
Yield10 Bioscience price target lowered to $1 from $7 at Ladenburg
11/18/19 National Securities
Yield10 Bioscience downgraded to Neutral from Buy at National Securities
PLUG Plug Power
$11.31 /

-0.73 (-6.06%)

08/03/20 H.C. Wainwright
Plug Power becoming 'go-to solution' for big box retailers, says H.C. Wainwright
07/09/20
Fly Intel: Top five analyst downgrades
07/09/20 Barclays
Plug Power downgraded to Equal Weight on valuation at Barclays
07/09/20 Barclays
Plug Power downgraded to Equal Weight from Overweight at Barclays
SMCI Super Micro Computer
$30.45 /

+0.35 (+1.16%)

06/11/20 Northland
Super Micro Computer initiated with an Outperform at Northland
06/05/20
Fly Intel: Top five analyst initiations
06/05/20 Loop Capital
Super Micro Computer initiated with a Buy at Loop Capital
06/04/20 Loop Capital
Super Micro Computer initiated with a Buy at Loop Capital
HCAT Health Catalyst
$34.96 /

-0.19 (-0.54%)

07/14/20 Citi
Health Catalyst initiated with a Buy at Citi
07/10/20 SVB Leerink
Health Catalyst price target raised to $40 from $32 at SVB Leerink
06/18/20 Stifel
Health Catalyst initiated with a Buy at Stifel
06/15/20 Evercore ISI
Health Catalyst assumed with an Outperform at Evercore ISI
LMND Lemonade
$62.84 /

-4.44 (-6.60%)

07/27/20
Fly Intel: Top five analyst initiations
07/27/20 Oppenheimer
Lemonade initiated with a Perform at Oppenheimer
07/27/20 Goldman Sachs
Lemonade initiated with a Sell at Goldman Sachs
07/27/20 Barclays
Lemonade initiated with an Equal Weight at Barclays
TRVN Trevena
$2.72 /

-0.42 (-13.38%)

09/03/19 H.C. Wainwright
Trevena's oliceridine 'close to the finish line,' says H.C. Wainwright
PSNL Personalis
$21.21 /

+0.17 (+0.81%)

11/14/19 Oppenheimer
Personalis price target lowered to $26 from $29 at Oppenheimer
09/26/19 BofA
Bruker, PerkinElmer, Personalis upgraded to Buy at BofA/Merrill
09/26/19 BofA
Personalis upgraded to Buy from Neutral at BofA/Merrill
GFF Griffon
$24.07 /

-0.285 (-1.17%)

01/14/20 Baird
Griffon upgraded to Outperform at Baird
01/14/20 Baird
Griffon upgraded to Outperform from Neutral at Baird
OSTK Overstock.com
$91.92 /

-3.66 (-3.83%)

07/31/20 DA Davidson
Overstock.com price target raised to $103 from $66 at DA Davidson
07/02/20 DA Davidson
Overstock.com price target raised to $66 from $33 at DA Davidson
05/12/20 Jefferies
Overstock.com 130% sales jump positive for Wayfair, says Jefferies
05/06/20 DA Davidson
Wayfair price target raised to $100 from $45 at DA Davidson
ADVM Adverum Biotechnologies
$15.59 /

-3.13 (-16.72%)

08/10/20 Piper Sandler
Adverum Biotechnologies price target raised to $30 from $25 at Piper Sandler
07/08/20 Cantor Fitzgerald
Adverum Biotechnologies price target raised to $36 from $21 at Cantor Fitzgerald
06/29/20 Piper Sandler
Adverum Biotechnologies should be bought on selloff, says Piper Sandler
06/26/20 Raymond James
Adverum Biotechnologies downgradedat Raymond James on abicipar CRL
YTEN Yield10 Bioscience
$6.53 /

+0.38 (+6.18%)

VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

TXG 10x Genomics
$96.78 /

+0.01 (+0.01%)

TSLA Tesla
$1,374.39 /

-45.48 (-3.20%)

TRVN Trevena
$2.72 /

-0.42 (-13.38%)

SMCI Super Micro Computer
$30.45 /

+0.35 (+1.16%)

RRGB Red Robin
$10.85 /

+0.86 (+8.61%)

PSNL Personalis
$21.21 /

+0.17 (+0.81%)

PLUG Plug Power
$11.31 /

-0.73 (-6.06%)

OSTK Overstock.com
$91.92 /

-3.66 (-3.83%)

OSPN OneSpan
$31.19 /

+1.28 (+4.28%)

MRNA Moderna
$68.94 /

-3.09 (-4.29%)

LRN K12
$47.31 /

-0.73 (-1.52%)

LMND Lemonade
$62.84 /

-4.44 (-6.60%)

KODK Eastman Kodak
$10.01 /

-0.665 (-6.23%)

IDN Intellicheck
$8.32 /

+0.08 (+0.97%)

HCAT Health Catalyst
$34.96 /

-0.19 (-0.54%)

GIII G-III Apparel
$11.99 /

+0.735 (+6.53%)

GFF Griffon
$24.07 /

-0.285 (-1.17%)

FBK FB Financial
$28.63 /

+0.92 (+3.32%)

CVET Covetrus
$23.04 /

-0.64 (-2.70%)

CNR Cornerstone Building Brands
$7.35 /

+0.1 (+1.38%)

CMBM Cambium Networks
$11.86 /

-0.31 (-2.55%)

AOSL Alpha & Omega
$11.44 /

+0.12 (+1.06%)

ADVM Adverum Biotechnologies
$15.59 /

-3.13 (-16.72%)

  • 14
    Aug
  • 12
    Aug
  • 13
    Aug
  • 12
    Aug
  • 12
    Aug
  • 12
    Aug
  • 08
    Jul
  • 02
    Jul
  • 19
    Jun
  • 19
    May
  • 14
    Feb
  • 12
    Feb
  • 12
    Feb
  • 06
    Dec
  • 11
    Oct
  • 12
    Sep
VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

TSLA Tesla
$1,374.39 /

-45.48 (-3.20%)

TRVN Trevena
$2.72 /

-0.42 (-13.38%)

PLUG Plug Power
$11.31 /

-0.73 (-6.06%)

MRNA Moderna
$68.94 /

-3.09 (-4.29%)

LRN K12
$47.31 /

-0.73 (-1.52%)

KODK Eastman Kodak
$10.01 /

-0.665 (-6.23%)

YTEN Yield10 Bioscience
$6.53 /

+0.38 (+6.18%)

VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

TSLA Tesla
$1,374.39 /

-45.48 (-3.20%)

RRGB Red Robin
$10.85 /

+0.86 (+8.61%)

PSNL Personalis
$21.21 /

+0.17 (+0.81%)

PLUG Plug Power
$11.31 /

-0.73 (-6.06%)

OSTK Overstock.com
$91.92 /

-3.66 (-3.83%)

MRNA Moderna
$68.94 /

-3.09 (-4.29%)

LRN K12
$47.31 /

-0.73 (-1.52%)

LMND Lemonade
$62.84 /

-4.44 (-6.60%)

KODK Eastman Kodak
$10.01 /

-0.665 (-6.23%)

IDN Intellicheck
$8.32 /

+0.08 (+0.97%)

HCAT Health Catalyst
$34.96 /

-0.19 (-0.54%)

GIII G-III Apparel
$11.99 /

+0.735 (+6.53%)

FBK FB Financial
$28.63 /

+0.92 (+3.32%)

CVET Covetrus
$23.04 /

-0.64 (-2.70%)

CMBM Cambium Networks
$11.86 /

-0.31 (-2.55%)

AOSL Alpha & Omega
$11.44 /

+0.12 (+1.06%)

ADVM Adverum Biotechnologies
$15.59 /

-3.13 (-16.72%)

VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

TSLA Tesla
$1,374.39 /

-45.48 (-3.20%)

TRVN Trevena
$2.72 /

-0.42 (-13.38%)

SMCI Super Micro Computer
$30.45 /

+0.35 (+1.16%)

RRGB Red Robin
$10.85 /

+0.86 (+8.61%)

PLUG Plug Power
$11.31 /

-0.73 (-6.06%)

OSTK Overstock.com
$91.92 /

-3.66 (-3.83%)

MRNA Moderna
$68.94 /

-3.09 (-4.29%)

LRN K12
$47.31 /

-0.73 (-1.52%)

LMND Lemonade
$62.84 /

-4.44 (-6.60%)

KODK Eastman Kodak
$10.01 /

-0.665 (-6.23%)

FBK FB Financial
$28.63 /

+0.92 (+3.32%)

Periodicals
Wall Street leaders happy with Harris pick as Biden running mate, CNBC says » 18:40
08/11/20
08/11
18:40
08/11/20
18:40
C

Citi

$53.76 /

+0.89 (+1.68%)

, SPX

S&P 500

$0.00 /

+ (+0.00%)

, SPY

SPDR S&P 500 ETF Trust

$332.82 /

-2.72 (-0.81%)

Wall Street leaders…

Wall Street leaders praised Joe Biden's pick of Senator Kamala Harris as his running mate in this year's presidential election, CNBC's Brian Schwartz reports. Finance executives, confident the pair has what it takes to defeat President Donald Trump, raved about Harris' experience in government, as well her fundraising abilities, Schwartz says. "I think it's great," said Marc Lasry, the CEO of investment firm Avenue Capital Group. "She's going to help Joe immensely. He picked the perfect partner." Brian Effron, co-founder of Centerview Partners, told CNBC that she was a "great choice" for vice president, while Citi's (C) Ray McGuire issued a similar message. Financial advisory firm Signum Global has already started telling its clients that the choice of the senator from California reinforces the notion that the Democratic ticket is more moderate than progressive, while Jon Henes, a partner at Kirkland & Ellis who was Harris' national finance chairman during her presidential campaign, told CNBC that the choice indicates that Biden has strong judgement. Reference Link

ShowHide Related Items >><<
SPX S&P 500
$0.00 /

+ (+0.00%)

C Citi
$53.76 /

+0.89 (+1.68%)

C Citi
$53.76 /

+0.89 (+1.68%)

07/20/20 Berenberg
Citi price target raised to $65 from $50 at Berenberg
07/17/20 Odeon Capital
Citi downgraded to Hold from Buy at Odeon Capital
07/15/20 BMO Capital
Citi price target raised to $87 from $82 at BMO Capital
07/15/20 Oppenheimer
Citi price target lowered to $101 from $106 at Oppenheimer
SPX S&P 500
$0.00 /

+ (+0.00%)

06/04/20 Keefe Bruyette
Mattis rebuke 'wake up call' for stock market, says Keefe Bruyette
03/11/20 Goldman Sachs
Goldman Sachs believes the S&P 500 bull market will soon end
02/27/20 Keefe Bruyette
Stock market may rally Monday on 'Biden bounce,' Keefe Bruyette says
02/24/20
Dow Jones futures decline over 800 points ahead of today's open
SPY SPDR S&P 500 ETF Trust
$332.82 /

-2.72 (-0.81%)

SPX S&P 500
$0.00 /

+ (+0.00%)

C Citi
$53.76 /

+0.89 (+1.68%)

SPX S&P 500
$0.00 /

+ (+0.00%)

C Citi
$53.76 /

+0.89 (+1.68%)

C Citi
$53.76 /

+0.89 (+1.68%)

SPY SPDR S&P 500 ETF Trust
$332.82 /

-2.72 (-0.81%)

SPX S&P 500
$0.00 /

+ (+0.00%)

C Citi
$53.76 /

+0.89 (+1.68%)

SPY SPDR S&P 500 ETF Trust
$332.82 /

-2.72 (-0.81%)

SPX S&P 500
$0.00 /

+ (+0.00%)

Hot Stocks
Google collaborates with USGS, Cal OES to send earthquake alerts » 18:34
08/11/20
08/11
18:34
08/11/20
18:34
GOOG

Alphabet

$1,478.80 /

-16.64 (-1.11%)

, GOOGL

Alphabet Class A

$1,479.23 /

-17.65 (-1.18%)

Google said in a blog…

Google said in a blog post that it is collaborating with the United States Geological Survey and California Governor's Office of Emergency Services to send earthquake alerts, powered by ShakeAlert, directly to Android devices in California. Developed by the nation's leading seismologists, the ShakeAlert system uses signals from more than 700 seismometers installed across the state by USGS, Cal OES, University of California Berkeley, and the California Institute of Technology, the company said. Reference Link

ShowHide Related Items >><<
GOOG Alphabet
$1,478.80 /

-16.64 (-1.11%)

GOOG Alphabet
$1,478.80 /

-16.64 (-1.11%)

08/03/20 Goldman Sachs
ADT Inc. price target raised to $17 from $9 at Goldman Sachs
08/03/20 William Blair
Alarm.com downgraded to Market Perform from Outperform at William Blair
08/03/20 Morgan Stanley
ADT Inc. price target raised to $17 from $7 at Morgan Stanley
08/03/20 Credit Suisse
ADT Inc. price target raised to $8.70 from $7 at Credit Suisse
GOOGL Alphabet Class A
$1,479.23 /

-17.65 (-1.18%)

08/10/20 Truist
Trade Desk price target raised to $450 from $250 at Truist
08/10/20 RBC Capital
ADT Inc price target raised to $16 from $10 at RBC Capital
08/03/20 William Blair
Alarm.com downgraded at William Blair on ADT/Google overhang
GOOG Alphabet
$1,478.80 /

-16.64 (-1.11%)

GOOG Alphabet
$1,478.80 /

-16.64 (-1.11%)

GOOG Alphabet
$1,478.80 /

-16.64 (-1.11%)

GOOGL Alphabet Class A
$1,479.23 /

-17.65 (-1.18%)

Hot Stocks
Owens & Minor CEO: We continue to focus on process improvement » 18:25
08/11/20
08/11
18:25
08/11/20
18:25
OMI

Owens & Minor

$14.79 /

+1.02 (+7.41%)

In an interview on…

In an interview on CNBC's Mad Money, Ed Pesicka said the company is continuing to find ways to increase production of PPE. "There is still an imbalance between supply and demand. We are starting to get product off new lines ahead of schedule," he noted. There is increased demand for PPE outside of healthcare, according to Pesicka. He said the company continues to pay down debt, eliminating 20% in last five quarters.

ShowHide Related Items >><<
OMI Owens & Minor
$14.79 /

+1.02 (+7.41%)

OMI Owens & Minor
$14.79 /

+1.02 (+7.41%)

08/11/20 Baird
Baird names Owens & Minor as Fresh Pick, sees 'unusual opportunity'
07/22/20 Baird
Owens & Minor upgraded to Outperform from Neutral at Baird
07/21/20 Baird
Owens & Minor upgraded to Outperform from Neutral at Baird
07/21/20 BofA
Owens & Minor upgraded to Buy at BofA after pre-announcement
OMI Owens & Minor
$14.79 /

+1.02 (+7.41%)

OMI Owens & Minor
$14.79 /

+1.02 (+7.41%)

OMI Owens & Minor
$14.79 /

+1.02 (+7.41%)

OMI Owens & Minor
$14.79 /

+1.02 (+7.41%)

Hot Stocks
ServiceNow's Chadwick sells 3,601 common shares » 18:25
08/11/20
08/11
18:25
08/11/20
18:25
NOW

ServiceNow

$421.19 /

-17.6 (-4.01%)

In a regulatory filing,…

In a regulatory filing, ServiceNow director Jonathan Chadwick disclosed the sale of 3,601 common shares of the company on August 10 at a price of $430.44 per share.

ShowHide Related Items >><<
NOW ServiceNow
$421.19 /

-17.6 (-4.01%)

NOW ServiceNow
$421.19 /

-17.6 (-4.01%)

07/30/20 Wells Fargo
ServiceNow price target raised to $525 from $405 at Wells Fargo
07/30/20 Canaccord
ServiceNow price target raised to $475 from $375 at Canaccord
07/30/20 Credit Suisse
ServiceNow price target raised to $465 from $460 at Credit Suisse
07/30/20 Stifel
Stifel 'not at all concerned' by 'mild disappointment' with ServiceNow guidance
NOW ServiceNow
$421.19 /

-17.6 (-4.01%)

NOW ServiceNow
$421.19 /

-17.6 (-4.01%)

NOW ServiceNow
$421.19 /

-17.6 (-4.01%)

Downgrade
Deere downgraded to Hold from Buy at Deutsche Bank » 18:24
08/11/20
08/11
18:24
08/11/20
18:24
DE

Deere

$193.27 /

+3.26 (+1.72%)

Deutsche Bank analyst…

Deutsche Bank analyst Nicole Deblase downgraded Deere to Hold from Buy with an $185 price target, citing valuation. The analyst notes that the stock has risen 24% since she launched coverage on the name, and much of recovery in its business appears to be priced in. Deblase adds that she sees the possibility of escalation in U.S./China trade tensions and increased competition as potential risks.

ShowHide Related Items >><<
DE Deere
$193.27 /

+3.26 (+1.72%)

DE Deere
$193.27 /

+3.26 (+1.72%)

08/11/20 Deutsche Bank
Deere downgraded to Hold from Buy at Deutsche Bank
07/23/20 OTR Global
Farm Equipment Manufacturers upgraded to Mixed from Negative at OTR Global
07/17/20 Jefferies
Deere price target raised to $200 from $165 at Jefferies
07/13/20
Fly Intel: Top five analyst upgrades
DE Deere
$193.27 /

+3.26 (+1.72%)

DE Deere
$193.27 /

+3.26 (+1.72%)

DE Deere
$193.27 /

+3.26 (+1.72%)

DE Deere
$193.27 /

+3.26 (+1.72%)

Downgrade
Deere downgraded to Hold from Buy at Deutsche Bank » 18:16
08/11/20
08/11
18:16
08/11/20
18:16
DE

Deere

$193.27 /

+3.26 (+1.72%)

Deutsche Bank analyst…

Deutsche Bank analyst Nicole Deblase downgraded Deere to Hold from Buy.

ShowHide Related Items >><<
DE Deere
$193.27 /

+3.26 (+1.72%)

DE Deere
$193.27 /

+3.26 (+1.72%)

07/23/20 OTR Global
Farm Equipment Manufacturers upgraded to Mixed from Negative at OTR Global
07/17/20 Jefferies
Deere price target raised to $200 from $165 at Jefferies
07/13/20
Fly Intel: Top five analyst upgrades
07/13/20 Baird
Deere upgraded to Outperform from Neutral at Baird
DE Deere
$193.27 /

+3.26 (+1.72%)

DE Deere
$193.27 /

+3.26 (+1.72%)

DE Deere
$193.27 /

+3.26 (+1.72%)

DE Deere
$193.27 /

+3.26 (+1.72%)

Hot Stocks
Moderna up over 11% at $77 per share after $1.5B mRNA-1273 award  18:10
08/11/20
08/11
18:10
08/11/20
18:10
MRNA

Moderna

$68.94 /

-3.09 (-4.29%)

 
ShowHide Related Items >><<
MRNA Moderna
$68.94 /

-3.09 (-4.29%)

MRNA Moderna
$68.94 /

-3.09 (-4.29%)

08/06/20 Barclays
Moderna COVID vaccine still has 'best-in-class potential,' says Barclays
08/05/20 Piper Sandler
Piper reiterates $134 target on Moderna, notes Q2 ended with $3.1B cash
08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
MRNA Moderna
$68.94 /

-3.09 (-4.29%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$68.94 /

-3.09 (-4.29%)

MRNA Moderna
$68.94 /

-3.09 (-4.29%)

MRNA Moderna
$68.94 /

-3.09 (-4.29%)

Syndicate
StoneCo offers to sell $1.0B in class A common stock » 18:00
08/11/20
08/11
18:00
08/11/20
18:00
STNE

StoneCo

$52.39 /

+5.34 (+11.35%)

J.P. Morgan Securities…

J.P. Morgan Securities LLC, Morgan Stanley and Citigroup Global Markets Inc. are acting as Global Coordinators in this offering.

ShowHide Related Items >><<
STNE StoneCo
$52.39 /

+5.34 (+11.35%)

STNE StoneCo
$52.39 /

+5.34 (+11.35%)

07/27/20 Goldman Sachs
StoneCo price target raised to $52 from $32 at Goldman Sachs
05/28/20 Guggenheim
StoneCo price target raised to $40 from $30 at Guggenheim
05/19/20 Citi
StoneCo price target raised to $30 from $28 at Citi
03/31/20 Citi
StoneCo price target lowered to $28 from $50 at Citi
STNE StoneCo
$52.39 /

+5.34 (+11.35%)

STNE StoneCo
$52.39 /

+5.34 (+11.35%)

STNE StoneCo
$52.39 /

+5.34 (+11.35%)

STNE StoneCo
$52.39 /

+5.34 (+11.35%)

Hot Stocks
TTEC Holdings director sells 20K shares of common stock » 17:56
08/11/20
08/11
17:56
08/11/20
17:56
TTEC

TTEC Holdings

$56.05 /

-0.83 (-1.46%)

In a regulatory filing,…

In a regulatory filing, TTEC Holdings discloses that its EVP of TTEC Engage Martin Deghetto sold 20K shares of common stock on August 7th in a total transaction size of $1.15M.

ShowHide Related Items >><<
TTEC TTEC Holdings
$56.05 /

-0.83 (-1.46%)

TTEC TTEC Holdings
$56.05 /

-0.83 (-1.46%)

08/10/20
Fly Intel: Top five analyst downgrades
08/10/20 Sidoti
TTEC Holdings downgraded to Neutral from Buy at Sidoti
07/23/20 Morgan Stanley
TTEC Holdings initiated with an Equal Weight at Morgan Stanley
01/17/20
Fly Intel: Top five analyst initiations
TTEC TTEC Holdings
$56.05 /

-0.83 (-1.46%)

  • 06
    Dec
TTEC TTEC Holdings
$56.05 /

-0.83 (-1.46%)

Hot Stocks
Moderna says U.S. government secures 100M doses of mRNA-1273 » 17:51
08/11/20
08/11
17:51
08/11/20
17:51
MRNA

Moderna

$68.94 /

-3.09 (-4.29%)

Moderna announced that…

Moderna announced that the U.S. government has secured 100M doses of mRNA-1273 as part of the U.S. government's goal of securing early access to safe and effective COVID-19 vaccines for the American people. The award of up to $1.525B is for the manufacturing and delivery of 100M doses of mRNA-1273 including incentive payments for timely delivery of the product. With the previous award of up to $955M from BARDA for the development of mRNA-1273 to licensure, the announcement brings the U.S. government commitments for early access to mRNA-1273 to up to $2.48B. Under the terms of the agreement, the U.S. government, as a part of Operation Warp Speed, will also have the option to purchase up to an additional 400M doses of mRNA-1273 from Moderna. The U.S. government has announced that consistent with its commitment to free access to COVID-19 vaccines, Americans will receive mRNA-1273 at no cost for the vaccine itself. As is customary with government-purchased vaccines, healthcare professionals could charge for the cost of administering the vaccine. "We appreciate the confidence of the U.S. government in our mRNA vaccine platform and the continued support," said Stephane Bancel, Moderna's Chief Executive Officer. "We are advancing the clinical development of mRNA-1273 with the ongoing Phase 3 study being conducted in collaboration with NIAID and BARDA. In parallel, we are scaling up our manufacturing capability with our strategic partners, Lonza, Catalent and Rovi, to address this global health emergency with a safe and effective vaccine."

ShowHide Related Items >><<
MRNA Moderna
$68.94 /

-3.09 (-4.29%)

MRNA Moderna
$68.94 /

-3.09 (-4.29%)

08/06/20 Barclays
Moderna COVID vaccine still has 'best-in-class potential,' says Barclays
08/05/20 Piper Sandler
Piper reiterates $134 target on Moderna, notes Q2 ended with $3.1B cash
08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
MRNA Moderna
$68.94 /

-3.09 (-4.29%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$68.94 /

-3.09 (-4.29%)

MRNA Moderna
$68.94 /

-3.09 (-4.29%)

MRNA Moderna
$68.94 /

-3.09 (-4.29%)

Syndicate
Seres Therapeutics offers to sell 8M shares of common stock » 17:48
08/11/20
08/11
17:48
08/11/20
17:48
MCRB

Seres Therapeutics

$20.05 /

-2.67 (-11.75%)

Cowen and Company, LLC…

Cowen and Company, LLC and Piper Sandler & Co. are acting as joint book-running managers for the offering. Canaccord Genuity LLC and Oppenheimer & Co. Inc. are acting as co-managers.

ShowHide Related Items >><<
MCRB Seres Therapeutics
$20.05 /

-2.67 (-11.75%)

MCRB Seres Therapeutics
$20.05 /

-2.67 (-11.75%)

08/11/20 H.C. Wainwright
Seres Therapeutics price target raised to $41 from $8 at H.C. Wainwright
08/11/20 Jefferies
Seres Therapeutics upgraded to Buy from Hold at Jefferies
08/11/20 Jefferies
Seres Therapeutics upgraded to Buy from Hold at Jefferies
08/11/20 Chardan
Seres Therapeutics price target raised to $32.50 from $12.50 at Chardan
MCRB Seres Therapeutics
$20.05 /

-2.67 (-11.75%)

MCRB Seres Therapeutics
$20.05 /

-2.67 (-11.75%)

MCRB Seres Therapeutics
$20.05 /

-2.67 (-11.75%)

Earnings
Lemonade sees FY20 revenue $86M-$88M, consensus $88.96M » 17:45
08/11/20
08/11
17:45
08/11/20
17:45
LMND

Lemonade

$62.84 /

-4.44 (-6.60%)

Sees FY20 adjusted EBITDA…

Sees FY20 adjusted EBITDA ($109M)-($106M).

ShowHide Related Items >><<
LMND Lemonade
$62.84 /

-4.44 (-6.60%)

LMND Lemonade
$62.84 /

-4.44 (-6.60%)

07/27/20
Fly Intel: Top five analyst initiations
07/27/20 Oppenheimer
Lemonade initiated with a Perform at Oppenheimer
07/27/20 Goldman Sachs
Lemonade initiated with a Sell at Goldman Sachs
07/27/20 Barclays
Lemonade initiated with an Equal Weight at Barclays
LMND Lemonade
$62.84 /

-4.44 (-6.60%)

  • 02
    Jul
LMND Lemonade
$62.84 /

-4.44 (-6.60%)

LMND Lemonade
$62.84 /

-4.44 (-6.60%)

Earnings
Lemonade sees Q3 revenue $14M-$15M, consensus $15.2M » 17:45
08/11/20
08/11
17:45
08/11/20
17:45
LMND

Lemonade

$62.84 /

-4.44 (-6.60%)

Sees Q3 adjusted EBITDA…

Sees Q3 adjusted EBITDA ($33M)-($32M).

ShowHide Related Items >><<
LMND Lemonade
$62.84 /

-4.44 (-6.60%)

LMND Lemonade
$62.84 /

-4.44 (-6.60%)

07/27/20
Fly Intel: Top five analyst initiations
07/27/20 Oppenheimer
Lemonade initiated with a Perform at Oppenheimer
07/27/20 Goldman Sachs
Lemonade initiated with a Sell at Goldman Sachs
07/27/20 Barclays
Lemonade initiated with an Equal Weight at Barclays
LMND Lemonade
$62.84 /

-4.44 (-6.60%)

  • 02
    Jul
LMND Lemonade
$62.84 /

-4.44 (-6.60%)

LMND Lemonade
$62.84 /

-4.44 (-6.60%)

Earnings
Lemonade reports Q2 EPS ($1.77), consensus (95c) » 17:44
08/11/20
08/11
17:44
08/11/20
17:44
LMND

Lemonade

$62.84 /

-4.44 (-6.60%)

Reports Q2 revenue…

Reports Q2 revenue $29.9M, consensus $29.31M. Reports Q2 adjusted EBITDA ($18.2M). Reports Q2 total customer count 814,160, up 84% year-over-year.

ShowHide Related Items >><<
LMND Lemonade
$62.84 /

-4.44 (-6.60%)

LMND Lemonade
$62.84 /

-4.44 (-6.60%)

07/27/20
Fly Intel: Top five analyst initiations
07/27/20 Oppenheimer
Lemonade initiated with a Perform at Oppenheimer
07/27/20 Goldman Sachs
Lemonade initiated with a Sell at Goldman Sachs
07/27/20 Barclays
Lemonade initiated with an Equal Weight at Barclays
  • 02
    Jul
LMND Lemonade
$62.84 /

-4.44 (-6.60%)

LMND Lemonade
$62.84 /

-4.44 (-6.60%)

Periodicals
SoftBank eyes over $10B in public investing, Bloomberg says » 17:33
08/11/20
08/11
17:33
08/11/20
17:33
SFTBY

SoftBank

$0.00 /

+ (+0.00%)

SoftBank is eyeing…

SoftBank is eyeing investments of over $10B in public stocks as part of a new asset management business, far exceeding the initial holdings that founder Masayoshi Son outlined to investors recently, Bloomberg's Giles Turner, Ruth David, and Eyk Henning report. The tally could be as high as the tens of billions, the authors say. Reference Link

ShowHide Related Items >><<
SFTBY SoftBank
$0.00 /

+ (+0.00%)

SFTBY SoftBank
$0.00 /

+ (+0.00%)

07/10/20 Nomura Instinet
SoftBank price target raised to 7,240 yen from 6,640 yen at Nomura Instinet
05/26/20 Citi
SoftBank price target lowered to 7,100 yen from 8,200 yen at Citi
03/24/20 Jefferies
SoftBank upgraded to Buy from Hold at Jefferies
02/13/20 HSBC
SoftBank price target raised to 7,000 yen after Sprint deal approval
SFTBY SoftBank
$0.00 /

+ (+0.00%)

SFTBY SoftBank
$0.00 /

+ (+0.00%)

Syndicate
Premier files to sell 50.14M shares of Class A common stock for holders  17:33
08/11/20
08/11
17:33
08/11/20
17:33
PINC

Premier

$35.33 /

+0.52 (+1.49%)

 
ShowHide Related Items >><<
PINC Premier
$35.33 /

+0.52 (+1.49%)

PINC Premier
$35.33 /

+0.52 (+1.49%)

05/12/20
Fly Intel: Top five analyst initiations
05/12/20 Cantor Fitzgerald
Premier initiated with an Overweight at Cantor Fitzgerald
04/13/20 SVB Leerink
Premier initiated with an Outperform at SVB Leerink
02/04/20 Piper Sandler
Piper Sandler cautious on Premier's Acurity/Nexera deal
PINC Premier
$35.33 /

+0.52 (+1.49%)

Earnings
Hudbay Minerals reports Q2 EPS (15c), consensus 18c » 17:31
08/11/20
08/11
17:31
08/11/20
17:31
HBM

Hudbay Minerals

$3.43 /

-0.065 (-1.86%)

Reports Q2 revenue…

Reports Q2 revenue $208.9M, consensus $364.97M. Reports Q2 copper output 18,026 tonnes, down 27%, and gold output up 7% from Q1. CEO Peter Kukielski says: "Our Manitoba operations continue to impress with record gold production this quarter and a significant increase in revenues over the first quarter. Our Constancia operations in Peru achieved a quick and efficient ramp up in mid-May after having been temporarily suspended due to COVID-19. Now that Constancia is fully operational, we have reissued production and cost guidance for Peru and are continuing to advance Pampacancha, with land clearing activities underway. The New Britannia gold mill refurbishment activities continue on budget and on schedule to increase Lalor's annual gold production to over 150,000 ounces by 2022. We are also pleased to announce an update to the resource estimates for the 1901 deposit which increases the total size of the deposit and demonstrates the gold potential in the Snow Lake camp through significantly increasing the gold content of the base metal zones while adding a new gold-rich zone to the resource estimate."

ShowHide Related Items >><<
HBM Hudbay Minerals
$3.43 /

-0.065 (-1.86%)

HBM Hudbay Minerals
$3.43 /

-0.065 (-1.86%)

07/21/20 National Bank
Hudbay Minerals price target raised to C$5.25 from C$4.25 at National Bank
07/20/20 Canaccord
Hudbay Minerals price target raised to C$7.50 from C$6 at Canaccord
07/09/20 Scotiabank
Hudbay Minerals price target raised to C$4.25 from C$4 at Scotiabank
05/29/20 BMO Capital
Hudbay Minerals upgraded to Outperform from Market Perform at BMO Capital
HBM Hudbay Minerals
$3.43 /

-0.065 (-1.86%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.